ArticleMolecules (Basel, Switzerland)2023
Nephroprotective Effect of Diosmin against Cisplatin-Induced Kidney Damage by Modulating IL-1β, IL-6, TNFα and Renal Oxidative Damage.
Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Evaluation of the effects of diosmin in cyclophosphamide-induced nephrotoxicity: an experimental animal study.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Riociguat Alleviates Cisplatin-Caused Kidney Injury by Suppressing Oxidative Stress and Inflammation.Biology · 2025Article
- Nanoliposomal Formulation ofFood science & nutrition · 2025Article
- Comparison of the nephroprotective effect of [6]-gingerol and the [6]-gingerol-β-cyclodextrin complex against cisplatin-induced AKI.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Khellin Mitigates Cisplatin-Induced Renal Injury by Targeting Oxidative Stress, Inflammation, and Apoptosis: Integration of Network Pharmacology, Molecular Docking, and Preclinical Validation.Pharmaceuticals (Basel, Switzerland) · 2025Article
- N-Dimethyl chalcone facilitated augmentation of IL-10 and diminution of TNF-α, IL-1β, IL-6, NFκB, and COX-2 in FCA-induced arthritic rat model.Inflammopharmacology · 2025Article
- Advances in nephroprotection: the therapeutic role of selenium, silver, and gold nanoparticles in renal health.International urology and nephrology · 2025Review
- Investigating the cardioprotective potential of quercetin against tacrolimus-induced cardiotoxicity in Wistar rats: A mechanistic insights.Open medicine (Warsaw, Poland) · 2025Article
- Inorganic Nanoparticles Containing Plant-Derived Compounds for Kidney Treatment.Bioinorganic chemistry and applications · 2025Review
- Evaluation of the Effect of Loratadine versus Diosmin/Hesperidin Combination on Vinca Alkaloids-Induced Neuropathy: A Randomized Controlled Clinical Trial.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Cisplatin (CP) is a platinum compound of the alkylating agent class that is used for the treatment of various types of cancer. However, CP treatments in cancer patients are accountable for nephrotoxicity, as it is a major adverse effect. Hence, this research study was proposed to investigate the nephroprotective effect of diosmin, a flavonoid glycoside of hesperidin derivatives against cisplatin-induced kidney damage. Wistar rats received a single intraperitoneal (i.p) injection of CP (7.5 mg/kg, i.p) to induce nephrotoxicity. The administration of CP significantly (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.